Available
Price range: $58.00 through $102.00
Strict Regulatory Notice: This agent is synthesized strictly for laboratory-based research and analytical purposes. It is not intended for human or veterinary use, nor for medical, household, or cosmetic applications. Please review our Terms of Service thoroughly before finalizing your acquisition.
10mg/mL Peg-400 solution (300mg/30mL)
30mg/mL MCT Oil (600mg/20mL)
| Parameter | Specification / Details |
|---|---|
| Primary Compound Name | YK-11 (Steroidal SARM / Myostatin Inhibitor) |
| CAS Registry Number | 1370003-76-1 |
| IUPAC Designation | (17α,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester |
| Synonyms / Trade Names | Myostine, YK11 |
| PubChem CID | 119058028 |
| Molecular Formula | C25H34O6 |
| Molar Mass / Weight | 430.54 g/mol |
| Physical Appearance | White to off-white crystalline powder (raw) / Clear or slightly tinted liquid (suspended) |
| Solubility Profile | Soluble in DMSO, Ethanol, and Propylene Glycol/PEG 400. Insoluble in water. |
| Tested Purity | ≥98% via HPLC |
| Active Ingredient (Total) | 300mg per 30mL vial |
| Dry / Powder Formulations | N/A (Liquid suspension) |
| Liquid / Solution Concentrations | 30mg/mL in MCT Oil carrier |
| Liquid / Solution Concentrations | 10mg/mL in a PEG 400 / Ethanol carrier |
| Alternative Formulations | Other DHT-derived research compounds or non-steroidal SARMs |
| Storage Guidelines | Store at room temperature (20°C to 25°C). Protect strictly from moisture, heat, and direct sunlight. |
| Estimated Shelf Life | 24 months from manufacture date. |
| Safety Documentation | Standard SDS available for YK-11 |
| Terms of Application | For laboratory research purposes only. Not for human or veterinary use. Investigated for its dual role as a partial agonist of the androgen receptor and its ability to induce follistatin expression, subsequently inhibiting myostatin in in-vitro cellular models (e.g., C2C12 myoblasts). |
Injectable YK11 is a prominent and highly unique subject within the field of musculoskeletal research. Unlike traditional non-steroidal SARMs, YK11 possesses a steroidal backbone structurally similar to dihydrotestosterone (DHT), serving researchers examining partial androgen receptor agonism coupled with profound myostatin inhibition.
At 4 Amino Labs, we provide this specialized compound in a highly purified format to ensure experimental reproducibility. By maintaining rigorous measurement standards, we provide the consistency required for longitudinal data integrity.
Scientific Literature Reference: The biochemical pathway of YK11 acting not just as an androgen receptor agonist, but fundamentally driving anabolism through the induced expression of follistatin (a primary myostatin inhibitor), is highly documented. See: Kanno, Y., et al. (2011). “Selective androgen receptor modulator, YK11, regulates myogenic differentiation of C2C12 myoblasts by follistatin expression.” Biological and Pharmaceutical Bulletin, 34(3), 318-323.
Our YK11 undergoes a multifaceted verification process. Each batch is subjected to independent High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) to ensure a purity threshold of ≥ 99%. This analytical rigor ensures the absolute structural integrity of the steroidal backbone.
Researchers utilizing YK11 typically focus on the following biochemical mechanisms:
To maintain the molecular integrity of YK11, the following storage parameters are recommended:
This substance is provided exclusively for in-vitro laboratory research and pre-clinical developmental testing. 4 Amino Lab does not condone or authorize the use of this product in any clinical setting or for personal consumption. Misuse of laboratory chemicals carries significant health risks. By purchasing, the researcher acknowledges the inherent risks and confirms they possess the necessary equipment and expertise to handle these materials safely. Those seeking injectable yk11 for sale should ensure all intended laboratory use complies with applicable regulations.
